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Abstract
Heart failure (HF) is characterized by contractile dysfunction associated with altered energy metabolism. This study was
aimed at determining whether resveratrol, a polyphenol known to activate energy metabolism, could be beneficial as a
metabolic therapy of HF. Survival, ventricular and vascular function as well as cardiac and skeletal muscle energy
metabolism were assessed in a hypertensive model of HF, the Dahl salt-sensitive rat fed with a high-salt diet (HS-NT).
Resveratrol (18 mg/kg/day; HS-RSV) was given for 8 weeks after hypertension and cardiac hypertrophy were established
(which occurred 3 weeks after salt addition). Resveratrol treatment improved survival (64% in HS-RSV versus 15% in HS-NT,
p,0.001), and prevented the 25% reduction in body weight in HS-NT (P,0.001). Moreover, RSV counteracted the
development of cardiac dysfunction (fractional shortening 234% in HS-NT) as evaluated by echocardiography, which
occurred without regression of hypertension or hypertrophy. Moreover, aortic endothelial dysfunction present in HS-NT was
prevented in resveratrol-treated rats. Resveratrol treatment tended to preserve mitochondrial mass and biogenesis and
completely protected mitochondrial fatty acid oxidation and PPARa (peroxisome proliferator-activated receptor a)
expression. We conclude that resveratrol treatment exerts beneficial protective effects on survival, endothelium–dependent
smooth muscle relaxation and cardiac contractile and mitochondrial function, suggesting that resveratrol or metabolic
activators could be a relevant therapy in hypertension-induced HF.
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Introduction
Heart failure (HF) is a complex and multicausal chronic
syndrome characterized by profound myocardial dysfunction
resulting in the inability of the cardiac pump to meet the
requirements of the body. Alterations in energy metabolism are
increasingly proposed as key events in the progression of the
pathology [1–3] with effects also in peripheral muscles, thus
suggesting a generalized metabolic myopathy in HF [4–6]. In
addition, the phosphocreatine (PCr) to ATP ratio, a marker of
energy metabolism of the myocardium has prognostic value in
dilated cardiomyopathy [7]. These energetic alterations mainly
originate from a down-regulation of genes involved in mitochon-
drial biogenesis and substrate utilization, the up-stream peroxi-
some proliferator-activated receptor (PPAR) gamma co-activator-
1a (PGC-1a) and its downstream transcription factors and nuclear
receptors [8,9] (for review see [10]). Moreover, the decreased
expression of PPARa in the failing heart leads to a marked
reduction in fatty acid (FA) utilization [11]. It is thus largely
accepted that a defective PGC-1a/PPARa axis plays a pivotal role
in the pathogenesis of HF [12]. The generalized deficiency in
energy metabolism, affecting substrate utilization, energy produc-
tion, transfer and utilization in HF, thus paves the way for a
metabolic therapy targeting energy starvation [2,4].
Resveratrol, a polyphenol with antioxidant, anti-apoptotic, anti-
inflammatory and metabolic properties was recently identified as an
activator of energy metabolism. Enhanced SIRT1 activity decreases
plasma glucose levels, improves insulin sensitivity, increases mito-
chondrial number and function, decreases adiposity, improves
exercise tolerance and potentially lowers body weight [13].
Resveratrol can induce mitochondrial biogenesis and improve fatty
acid oxidation (FAO) in many tissues via a mechanism involving
sirtuins and AMP-activated protein kinase (AMPK) [14,15]. In the
heart, resveratrol decreases pressure overload-induced hypertrophy
and contractile dysfunction [16–20]. A diet rich in polyphenols has
been shown to reduce cardiovascular risk and induce vascular
protection [21] and may exert anti-hypertensive and antiatherogenic
effects [22]. Moreover resveratrol-rich extracts upregulate PGC-1a
and PPARa cardiac expression and/or activity [23]. Because of its
positive effects on vascular function and energy metabolism, we
hypothesized that resveratrol could also have beneficial effects in HF.
Therefore we examined in an experimental model, the Dahl-salt
sensitive (DSS) rat, whether resveratrol is protective against the
development of HF and associated metabolic dysfunction.
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Resveratrolimprovessurvivalandpreventsbodymass loss
HS-NT animals had a low survival rate (7/48 of HS-NT rats, i.e.
14.6%), but this was largely increased with resveratrol treatment (9/
14 of HS-RSV rats, i.e. 64.3%) (Figure 1A). Thus resveratrol
treatment was strongly protective. At sacrifice, the body weight of
HS-NT rats was 25% lower than that of both LS controls and HS-
RSV rats (Figure 1B). Heart weight (absolute and normalized to
tibia length) was significantly increased (by 33% and 35%
respectively) in HS-NT animals (p,0.001) relative to LS animals
and did not change with resveratrol treatment (Table 1). In HS-NT
lung weight was increased and decreased by resveratrol only when
related to body mass. The increase in kidney weight in HS-NT was
moderately prevented by resveratrol treatment (Table 1). Total
cholesterol, HDL and LDL were significantly increased in HS-NT
compared to LS animals and tended to decrease with RSV
treatment. No significant change in blood triglycerides and glucose
was observed whatever the groups (Table S1).
Resveratrol improves cardiac function and remodeling
without changing blood pressure
At 3 weeks, HS rat hearts had increased wall thickness (Table S2)
and calculated ventricular mass compared with LS hearts
(Figure 2B) with unaltered fractional shortening (FS, Figure 2C).
Eight weeks later, ventricular mass was further increased both in
HS-NT (+47%), and HS-RSV (+33%) compared to LS, with no
significant difference between the two groups. HS-NT rats showed
systolic dysfunction, with a 34% reduction in fractional shortening
(FS, Figure 3C), 62% increase in end-systolic left ventricle (LV)
diameter and 23% decrease in cardiac output, as well as diastolic
dysfunction assessed by Doppler tissue imaging [24] (Table 1)
whereas end-diastolic LV diameter was the same as in low salt
controls (Figure 2D). No major change in intrinsic mechanical
properties could be observed with the exception of the hill
coefficient of calcium sensitivity (Table S3). Remarkably, both
diastolic and systolic dysfunction was prevented by resveratrol
treatment. Resting, maximal and mean blood pressure (BP) was
alreadyincreasedinHScompared with LSanimalsat 3weeks (from
15264 mmHg versus 11669 mmHg, respectively), with no further
increase occurring at 11 weeks in either HS-NT or HS-RSV groups
(Figure 2E, Table S2). Thus resveratrol prevented cardiac
dysfunction without affecting blood pressure and cardiac mass.
Expression of atrial natriuretic factor (ANF), brain natriuretic
peptide (BNP) and myosin heavy chain b (b-MHC) mRNA, all
markers of cardiac remodeling, was highly up-regulated in HS-NT
animals, whereas in resveratrol-treated animals the increase in
ANF was attenuated (Figure 2F). Similarly, in HS-NT animals
there was a great decrease in mitochondrial and cytosolic creatine
kinases (miCK and MM-CK) activities, markers of metabolic
disturbances in HF, whereas mi-CK activity was maintained at the
level of controls in HS-RSV animals (Figure 2G). The protein
content of calcium metabolic markers like SERCA and calseques-
trin did not significantly differ between these groups (Table S3).
Resveratrol protects endothelial function
Carbachol-dependent relaxation of aorta after contraction
induced by prostaglandin F2a was impaired in HS-NT animals
compared with LS animals (Figure 3A). This impairment was
completely prevented by resveratrol treatment. When nitric oxide
(NO) was directly provided by S-nitrosothiol-N-acetyl-penicilla-
mine (SNAP), a significant rightward shift was observed (p,0.001)
in HS-NT rats that was not corrected by resveratrol (Figure 3B),
suggesting an endothelium- and NO-dependent protective effect of
resveratrol. Indeed, eNOS protein content was decreased in HS-
NT and preserved by resveratrol treatment (Figure 3C).
Resveratrol improves mitochondrial respiration,
biogenesis and substrate utilization
Both maximal cardiac fiber oxidative capacity and citrate synthase
(CS) activity were reduced in HS-NT rats but were preserved in HS-
RSV rats compared with LS controls (Figure 4A and B), while COX
activity was similar in all three groups. Expression levels of genes
involved in energy metabolism are presented in Figure S1. There was
a modestdecrease in the expression of PGC-1aand its transcriptional
cascade, key modulators of mitochondrial biogenesis, which were not
prevented by resveratrol treatment (Figure 4C). Interestingly,
expression of proteins involved in mitochondrial fusion was decreased
in HS-NT animals, two of which (Mfn1 and OPA1) were restored in
HS-RSV rats (Figure 4D).
Sarcoplasmic reticulum (SR) calcium uptake capacity with all
substrates was not changed (Table S3), whereas the ability of
mitochondria to supply energy to the SR-ATPase was decreased in
HS-NT versus LS animals and was completely preserved in HS-
RSV animals (Figure 4E). No significant change was observed in
energy supply by CK. This suggests that the close contacts
between SR and mitochondria, necessary for efficient energy
transfer, are preserved by resveratrol.
Decreased FAO is an early event in the failing heart. Addition
of palmitoyl CoA+carnitine, palmytoylcarnitine, pyruvate, and
glutamate resulted in lower respiration rates in HS-NT compared
to LS rats, and this was completely prevented with resveratrol
treatment (Figure 5A). Moreover, when respiration was normal-
ized to the maximal respiration rate in the presence of all
substrates (Figure 5B), the results clearly showed a selective
decrease in mitochondrial FAO in HS-NT rats, which was
prevented with resveratrol treatment. Accordingly, expression of
the nuclear transcription factor controlling FAO, PPARa, as well
as its target genes involved in FA transport (CPT-1b) and
oxidation (MCAD, LCAD), or carbohydrate utilization (PDK4),
was decreased in the heart of HS-NT. Expression level of PPARa,
CPT-1b and MCAD was preserved in HS-RSV animals
compared with LS animals (Figure 5C).
Skeletal muscles also suffer from energy starvation in HF. In
soleus muscle as in cardiac muscle, the decrease in oxidative
capacity was preserved by resveratrol (Figure 5D) as was the
specific decrease in mitochondrial fatty acid oxidation (Figure 5E).
Signaling pathways potentially involved in beneficial
effects of resveratrol
AMPK protein content and phosphorylation as well as
phosphorylation of ACC, its main target, did not differ between
groups at the end of experiments (Figure 6A). However AMPK
activity showed an early increase after 48 hours in RSV-treated
cardiomyocytes (Figure 6B). Calcineurin transcriptional activity
was estimated by measuring the expression of MCIP1, a known
target of NFAT [25]. MCIP1 expression was increased in HS-NT
and not influenced by resveratrol (Figure 6C), in accordance with
the maintained hypertrophy. Neither expression nor activity of
SIRT1 was changed (Figure 6C).
Discussion
The main purpose of this study was to investigate the use of
resveratrol as a potential metabolic therapy for hypertension-induced
HF. Resveratrol treatment resulted in 1) an increase in survival rate
by more than 50%; 2) complete preservation of myocardial function;
3) prevention of endothelial dysfunction; and 4) preservation of
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and FA utilization, a well as cardiac energy transfer. These beneficial
effects of resveratrol occurred despite the continued presence of
cardiac hypertrophy and hypertension in this model.
DSS rats present signs of heart failure
The high salt diet rapidly induced severe hypertension followed
by ventricular hypertrophy and LV dysfunction without dilatation,
hypercholesterolemia and a high mortality rate. In parallel,
markers of cardiac remodeling were sharply upregulated;
metabolic markers of HF such as CK isoenzymes and CS were
decreased while calcium metabolism markers were not signifi-
cantly altered. However, there was no clear sign of pulmonary
edema and no ascites. Severe body wasting, which is associated
with poor prognosis in HF [26], started at five weeks and was
associated with increased mortality rate. DSS rats thus developed
ventricular dysfunction with early signs of HF.
Resveratrol treatment improves survival and cardiac
function
Treatment of HSrats with resveratrolimproved cardiac function,
concomitant with a remarkable increase in survival rate. The high
mortality rate of DSS rats is due inter alia to stroke, renal failure and
HF. As already reported [27], resveratrol blunted the up-regulation
of stress markers, suggesting attenuation of the stress response of the
myocardium. These results match those obtained in SHR and
Figure 1. Resveratrol treatment increases survival and prevents body wasting in HS rats. (A) Kaplan-Meier survival analyses for low salt
(LS, N=9), high salt (HS, N=48) and high salt treated with resveratrol (HS-RSV, N=14) groups showed decreased survival of HS-NT compared to LS
groups (log-rank: x
2=35.29, ***P,0.00001). Survival in HS-RSV rats was decreased compared to LS rats (log-rank: x
2=4.75, *P=0.041) but was
significantly higher than HS-NT rats (log-rank: x
2=39.78,
$$$P=0.0007). B. The HS-NT group showed continuous weight loss from the fifth week of salt
intake compared to LS. Resveratrol completely prevented HF-induced weight loss. *P,0.05, **P,0.01, ***P,0.001 vs LS;
$P,0.05,
$$P,0.01,
$$$P,0.001 vs HS-NT.
doi:10.1371/journal.pone.0026391.g001
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without affecting BP [17,18,27]. In DSS rats, the renal hypertrophy
is mainly the result of fibrosis induced by activated inflammatory or
immune processes, which, in turn, depend on oxidative stress [28],
while aldosterone seems to play a role on glomerulosclerosis,
podocyte [29] non-related to the hypertension. This effect could
result from local anti-oxidant activity of RSV.
Interestingly, in line with the maintained elevated BP,
improvement of cardiac function and survival in DSS rats was
not accompanied by a prevention of ventricular wall thickening
and hypertrophy. The anti-hypertrophic effects of resveratrol was
reported in animal models [30] associated with the circulating
renin-angiotensin system (RAS) activation. This system may be
blunted by RSV treatment [22,31] thus reducing the cardiac
hypertrophy. In contrast, in DSS rats, circulating RAS is rather
inhibited [32] and hypertension is mostly linked to blood volume
expansion [33] so that potential anti-RAS activity of RSV does not
reduce hypertension. This suggests that resveratrol may have
separate, beneficial effects on hypertension and cardiac hypertro-
phy, and thus the benefits of resveratrol may depend on the
etiology of HF. Interestingly, stimulation of carbohydrate
metabolism by activation of pyruvate kinase induced similar
beneficial effects without reducing BP and hypertrophy [34].
Resveratrol prevents endothelial dysfunction
Another pathological event in HF is endothelial dysfunction
resulting in increased peripheral resistances and increased load to
the myocardium. This endothelial dysfunction is due to a decrease
in NO production resulting in impaired smooth muscle relaxation.
In HS-NT animals, the impaired vasodilatation could be
attributed to the sharp decrease in eNOS protein content inducing
a decrease in NO production. The moderate decrease in the
sensitivity of vascular relaxation to NO may also play a role in the
reduced response to carbachol.
DSS rats also demonstrate high level of vascular fibrosis found
in aortic tunica media and tunica adventitia [35], which increases
the vascular rigidity thus contributing to the hypertension.
Probably, such rigidity was not corrected by RSV and this
explains why improved endothelial function in aorta did not lead
to an attenuation of the hypertension. Further studies on small
arteries need to be conducted in order to elucidate this question.
Polyphenols are known to exert positive effects on endothelial
function and cardiac function in obesity [36]. The remarkable
improvement of endothelial function by resveratrol in HS animals
treated with RSV could be achieved through up-regulation of
eNOS expression that normalizes vasodilatation.
Resveratrol improves mitochondrial function, fatty acid
utilization and energy transfer
Altered energy metabolism, particularly mitochondrial dys-
function, is hallmark of HF that affects both cardiac and skeletal
muscles [5,6,37,38]. HS-NT rats presented signs of myocardial
metabolic disorders with reduced oxidative capacity, CS activity
and miCK content, and a global downregulation of genes
Table 1. Structural and, functional parameters from LS, HS and RSV-treated rats.
LS HS-NT HS-RSV
Anatomy (N=9) (N=7) (N=9)
Body weight (BW, g) 40065 295627*** 393614
$$$
Tibia length (TL, cm) 4.4960.02 4.3960.05* 4.560.01
$
Heart weight (HW, g) 1.3560.03 1.7960.11*** 1.7860.05***
HW/BW (mg/g) 3.460.1 6.360.6*** 4.660.3*
,$$
HW/TL (mg/cm) 30167 406623*** 396612***
Lung W/TL (mg/cm) 42164 493659 482619
LW/BW (mg/g) 4.760.1 7.761.3* 5.660.4
$
Kidney W/TL (mg/cm) 30767 596627*** 501633***
,$
KW/BW (mg/g) 3.460.1 9.260.7*** 5.960.6**
,$$$
Echocardiography (N=8) (N=8) (N=9)
IVSd (mm) 1.6160.10 2.0660.12* 1.9360.07*
PWTd (mm) 1.8460.09 1.9660.15 2.1260.09
Telediastolic volume (ml) 0.9160.04 1.2360.16 0.9960.08
Telesystolic volume (ml) 0.0860.01 0.3460.06*** 0.1460.04
$$
Ejection fraction (%) 91.760.8 73.763.3*** 87.462.2
$$$
Cardiac output (ml/min) 311613 241626* 301612
$
Doppler analysis (N=5) (N=6) (N=9)
Eann (m/s) 0.08260.01 0.04660.003*** 0.06760.003***
,$$
E/Eann 14.261.9 22.063.2* 17.161.2
HW: heart weight; IVSd: interventricular septum in diastole; PWTd: posterior wall in diastole; TL: tibia length.
*P,0.05,
***P,0.001 vs LS;
$P,0.05,
$$P,0.01,
$$$P,0.001 vs HS-NT.
doi:10.1371/journal.pone.0026391.t001
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and their downstream target genes, similar to numerous HF
models including DSS rats [8–10,12,34,34,39,40]. Resveratrol
preserved cardiac and skeletal muscle oxidative capacity and
mitochondrial enzyme activities, with no major changes in
expression of the mitochondrial biogenesis transcription cas-
cade.
In HS-NT rats, the specific reduction in mitochondrial FAO
capacity was accompanied by down-regulation of genes controlling
FAO, PPARa and its downstream targets. Remarkably, these
alterations were prevented by resveratrol treatment, independently
of changes in triglyceridemia. These results are consistent with the
beneficial effects of grape extracts on PPARa and PGC-1a observed
in DSS rats [23] and the PPARa-dependent beneficial effect of
Figure 2. Resveratrol preserves cardiac function, with no effect on hypertrophy or hypertension. Cardiac morphology and function were
assessed by echocardiography. (A) Representative M-mode images of the LV in LS, HS-NT and HS-RSV groups after 11 weeks of conditioning. (B)
Calculated left ventricular mass and (C) fractional shortening (FS) at 3 and 11 weeks. (D) End-diastolic and end-systolic left ventricle diameter (LVDd
and LVDs, respectively) at 11 weeks. (E) Mean arterial blood pressure. (F) Markers of remodeling: ANF (atrial natriuretic factor), BNP (brain natriuretic
protein) b-MHC (b myosin heavy chain) and (G) energy metabolism miCK and MM-CK (mitochondrial and myofibrillar creatine kinase). Between 6 and
9 animals per group. *P,0.05, **P,0.01, ***P,0.001 vs LS;
$P,0.05,
$$P,0.01,
$$$P,0.001 vs HS-NT.
doi:10.1371/journal.pone.0026391.g002
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estingly, our results indicate that FAO activation can be associated
with improved cardiac function, provided that a concomitant
increase in mitochondrial capacity ensures proper FA utilization.
Decreased energy transfer by the CK system is also a hallmark
of HF [37], characterized by a decrease in total and miCK
activity, the latter being completely normalized by resveratrol
treatment. This suggests that maintaining energy metabolism can
help preserve cardiac contractile function and survival.
Mitochondria are involved in permanent fusion and fission
events. Fission requires the dynamin-related protein 1 (Drp1),
whereas fusion is mediated by two dynamin-related proteins
involved in outer membrane fusion, mitofusins (Mfn1 and Mfn2),
and OPA1 (Optic atrophic type 1 protein) which is localized at the
inner membrane (for review see [42]). In HS-NT rats, expression
of fusion proteins was decreased, suggesting a shift towards
increased fragmentation of the mitochondrial network. Again,
resveratrol treatment prevented Mfn1 and OPA1 changes thus
tending to normalize the fusion/fission balance.
Finally, resveratrol beneficial effects on mitochondrial biogenesis
and dynamics may explain the conservation of energetic coupling
between mitochondria and the SR-ATPase. Direct energy cross talk
between mitochondria and energy consuming sites [43] is driven by
restricted diffusion of adenine nucleotides and is facilitated by the
juxtaposition of sites that produce and consume energy. HF is
characterized by impaired intracellular organization and a decrease
in SR calcium storage capacity, which is directly linked to a local
decrease in ATP/ADP ratio [44]. Such a defect in mitochondria/
SR-ATPase interaction was also evident in the HS-NT group, and
was again prevented by resveratrol treatment. This reveals a novel
effect of resveratrol on energy transfer and supply.
Importantly, these resveratrol-mediated effects are not a
consequence of reduced hypertension or cardiac hypertrophy.
Mode of action of resveratrol
In view of the pleiotropic effects of RSV, it is likely that the
beneficial effects of resveratrol in HF are multifactorial and involve
multiple signaling pathways acting on a variety of cellular targets
(Figure 7). The major effect of resveratrol was to abolish the down-
regulation of PPARa and modestly prevent PGC-1a transcription
cascade and mitochondrial lipidoxidation decrease. Interestingly, the
cardioprotective and neuroprotective effects of resveratrol (and
grapes) were shown to depend on PPARa and to involve improved
lipid metabolism and inflammation [23,41,45]. Resveratrol effects
Figure 3. Endothelial function is preserved in aorta from resveratrol-treated rats. (A) Carbachol-induced relaxation of aortic rings
precontracted with prostaglandin-F2a (PGF2a). (B) Endothelium-independent vasodilatation assessed using a NO donor (SNAP, S-nitrosothiol-N-
acetyl-penicillamine) on PGF2a-preconstricted aorta rings. Between 6–8 experiments per group. (C) Western blot analysis of eNOS expression of LS
(N=4), HS-NT (N=5) and HS-RSV (N=7) aortas. *P,0.05, ***P,0.001 vs LS;
$P,0.05,
$$$P,0.001 HS-RSV vs HS-NT.
doi:10.1371/journal.pone.0026391.g003
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dependent deacetylation as seen in skeletal muscle [46] but cardiac
SIRT1 expression and activity were not altered in HS-NT and HS-
RSV groups. However, lack of effect of resveratrol on PGC-1a
acetylation in heart, was already reported in resveratrol-treated mice
[14]. AMPK, is a central target for the metabolic effects of resveratrol
and an important player in modulating energy metabolism [15].
Although activated for short term resveratrol treatment of cardio-
myocytes, AMPK activation was unchanged in HS-NT and
resveratrol-treated rats at the end of treatment. The increased
calcineurin transcriptional activity in HS-NT rats was not prevented
by resveratrol, consistent with the maintained hypertrophy. More-
over it should be noted that resveratrol may also indirectly improve
cardiac energy metabolism through its vasorelaxing effect, which
could ameliorate perfusion and enhance oxygen and substrate
delivery to the heart and the periphery. Finally, the beneficial
cardiovascular and metabolic effects of resveratrol could also result
from its phytooestrogenic properties [47,48].
Conclusions
The present study was aimed at investigating the relevance of a
metabolic therapy of HF using resveratrol. Our data show multiple
beneficial effects of resveratrol in hypertension-induced HF, with
increased survival, reduced body wasting and improved cardiac
and endothelial function in particular. The major metabolic effect
of resveratrol in both cardiac and skeletal muscles was to restore
the expression of PPARa and attenuate PGC-1a transcription
cascade down-regulation and mitochondrial lipid oxidation
Figure 4. Cardiac mitochondrial function and biogenesis. (A) Maximal mitochondrial respiration of skinned fibers with 2 mM ADP, 4 mM
malate, 0.1 mM palmitoylCoA, 0.15 mM palmitoylcarnitine, 1 mM pyruvate and 10 mM glutamate. (B) Citrate synthase (CS) and cytochrome oxidase
(COX) activities, markers of mitochondrial mass. (C) mRNA levels of PGC-1a (peroxisome proliferator-activated receptor gamma coactivator 1a), Nrf2
(nuclear respiratory factor 2), mtTFA (mitochondrial transcription factor A), ERRa (estrogen-related receptor a), COX1 and IV (cytochrome c oxidase I
and IV subunits). (D) mRNA levels of the fission protein Drp1 (dynamin-related protein 1) and the fusion proteins Mfn (mitofusin) 1 and 2 and OPA1
(optic atrophy 1). (E) Energetic coupling efficiency between sarcoplasmic reticulum ATPase and mitochondria or bound creatine kinases (CK) assessed
by the ratio of calcium uptake under different energetic conditions (ATP+MITO+CK, ATP+MITO, ATP+CK, see Methods S1) to the uptake with ATP
only. mRNA levels are normalized to LS group taken as 1. Between 6 and 9 animals per group. *P,0.05, **P,0.01, ***P,0.001 vs LS;
$P,0.05,
$$P,0.01 vs HS-NT.
doi:10.1371/journal.pone.0026391.g004
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effects of resveratrol (and grapes) were shown to depend on
PPARa and to involve improved lipid metabolism and inflamma-
tion [23,41,45]. Indeed, resveratrol completely prevented cardiac
FA utilization reduction and improved mitochondria-driven
energy supply while preserving expression of mitochondrial fusion
protein. This suggests that amelioration of energy metabolism may
contribute to the regression of HF independent of cardiac
hypertrophy. Interestingly, a recent study describing the metabolic
remodeling of the failing heart showed that activation of
carbohydrate metabolism with dichloroacetic acid provided a
similar improvement in cardiac function and survival [34].
Altogether this highlights the relevance of metabolic therapy in
HF. Resveratrol and other metabolic activators are thus interesting
candidates for preventive metabolic therapy in HF.
Methods
Detailed Methods are presented in the supplemental file
(Methods S1).
Ethics Statements
All experiments were performed in conformity with the
European Community guiding principles in the care and use of
Figure 5. Resveratrol improves cardiac and soleus muscle fatty acid utilization. (A) Mitochondrial substrate utilization assessed by
respiration of permeabilized cardiac fibers using cumulative addition of 2 mM ADP 4 mM malate, 1 mM carnitine and 0.1 mM palmitoylCoA, 0.15 mM
palmitoylcarnitine, 1 mM pyruvate and 10 mM glutamate. (B) Respiration normalized to the maximal respiration rate and measured in the presence
of all of the substrates revealed decreased fatty acid oxidation. (C) mRNA levels of PPARa (peroxisome proliferator-activated receptor a), LCAD (long-
chain acylCoA dehydrogenase), MCAD (middle-chain acylCoA dehydrogenase), CPT-Ib (carnitine palmitoyltransferase Ib), PDK4 (pyruvate
dehydrogenase kinase 4). (D) Mitochondrial substrate utilization of permeabilized soleus fibers. (E) Normalized respiration, indicating decreased
fatty acid oxidation by soleus mitochondria. Between 7 and 9 animals per group. mRNA levels were normalized to LS group taken as 1. *P,0.05,
**P,0.01, ***P,0.001 vs LS;
$P,0.05,
$$P,0.01,
$$$P,0.001 vs HS-NT.
doi:10.1371/journal.pone.0026391.g005
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Authorizations to conduct animal experiments were obtained from
the French Ministe `re de l’Agriculture, de la Pe ˆche et de
l’Alimentation (no. 92-284, June 27, 2007).
Animals conditioning
The Dahl salt-sensitive rats (DSS) were chosen as a model of
hypertension. Seven week-old male DSS rats (Charles River
France) were randomly divided in two groups: 9 rats were fed a
low-salt diet (0.3% NaCl) for 11 weeks as controls (LS rats) and 62
rats were fed a high-salt diet (8% NaCl) for 3 weeks (HS rats). The
HS group was then subdivided into two groups for 8 weeks: a non-
treated group (HS-NT; n=48) and a resveratrol-treated group
(HS-RSV; n=14; 18 mg/kg/day in the diet). Diets were
manufactured by UPAE-INRA (INRA, Jouy-en-Josas, France)
and composition is given in Table S4. The animals were housed 1
per cage in a temperature-controlled room (22uC), with a 12/12 h
light/dark cycle, and were provided food and water ad libitum.
Diets were manufactured by UPAE-INRA (INRA, Jouy-en-
Josas, France) and composition is given in Table S1. The dose of
resveratrol of <20 mg/kg/d proved to be efficient in preventing
pulmonary hypertension [49] and in vasoprotection [50] and to
have no toxicity [51].
Echocardiography and blood pressure measurements
Echocardiography was performed at 3 and 11 weeks of diet
treatment using a 12 MHz transducer (Vivid 7, General Electric
Healthcare) under 2.5% isoflurane gas anesthesia. Two-dimen-
sional-guided (2D) M-mode echocardiography was used to
determine wall thickness and left ventricular chamber diameter
Figure 6. Resveratrol and signaling pathways. (A) Total and phosphorylated AMPK (AMP-activated kinase) and ACC (acylCoA carboxylase) were
unchanged in ventricles from LS (n=7), HS-NT (n=6) and HS-RSV (n=7) groups. (B) AMPK activation induced in adult rat ventricular myocytes after
48 h of resveratrol treatment (n=6). (C) SIRT1 activity and expression were unchanged, and calcineurin transcriptional activity assessed by measuring
the expression of its target gene MCIP1 was increased in HS-NT rats but not affected by resveratrol treatment. mRNA levels normalized to LS group
taken as 1. *P,0.05, **P,0.01 vs LS or control.
doi:10.1371/journal.pone.0026391.g006
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fractional shortening (FS) or ejection fraction (EF%). Left
ventricular mass was calculated according to the Penn formula
home-adapted for the rat heart: (LVM=1.046[(Dtd+SIV+PP)
3
2(Dtd)
3]). Doppler at the mitral valve was used to measure E and
A waves when possible and Doppler tissue imaging was used to
assess early diastolic lateral mitral annulus velocity as an estimate
of left ventricle diastolic function [24].
Arterial blood pressure was measured in conscious, restrained
rats using a tail-cuff system (CODA
TM 2 system, EMKA
Technologies France) in a dark temperature-controlled room
(22uC) in the morning. Rats were subjected to 15 acclimation
measurements in restraint holder then blood pressure was
calculated from the average of 10 measurement cycles.
Blood assays and sacrifices
At the end of the conditioning period, all non-fasted rats were
anesthetized by intraperitoneal injection of pentobarbital
(200 mg/kg) at 10 am. Depth of anesthesia was checked by toe
pinch before the start of surgery. Whole blood was sampled for
lipid and glucose profile analysis using a clinical Cholestech LDX
blood analyzer (Cholestech LDX system, GaiaMed). The heart
was then quickly removed for euthanasia then soleus muscles and
aorta were collected. Part of tissue was immediately used for
functional experiments, and another part was rapidly frozen and
kept at 280uC for further investigations.
Aortic reactivity
Vascular function was studied on aorta rings with preserved
endothelium mounted in a myograph under optimal and stabilized
resting tension. After a 60 min equilibration period in Krebs
solution [52], contractile capacity of arteries was evaluated using
Krebs solution containing 80 mM of KCl. A submaximal
concentration of prostaglandin F2a (PGF2a) was applied to
produce a pre-contraction of 80%. Endothelium-dependent
relaxation was then assessed by the addition of increasing amounts
of carbachol (10
29 to 3610
25 M) while endothelium-independent
relaxation was assessed directly using the nitric oxide (NO) donor
S-nitrosothiol-N-acetyl-penicillamine (SNAP, 10
29 to 10
25 M).
Mitochondrial function
Oxygen consumption was measured on saponin-permeabilized
cardiac and soleus fibers [53]. Maximal respiration rates and
sensitivity of mitochondrial respiration to carbohydrates and fatty
acids were evaluated using an adapted protocol [54]. Oxygen
consumption was followed in the presence of 2 mM ADP and
4 mM malate, by successive additions of substrates: palmitoylCoA
0.1 mM plus carnitine 1 mM, palmitoylcarnitine 0.15 mM,
pyruvate 1 mM and glutamate 10 mM. Maximal respiration was
measured in the presence of all these mitochondrial substrates.
Rates of respiration are given in mmoles O2/min/g dry weight
(dw). Two to three experiments were performed for each muscle
and each protocol.
Energy supply on SERCA activity
Local energy control of the sarcoplasmic reticulum (SR) ATPase
was assessed using saponin-skinned fibers from papillary muscle
mounted on a stainless-steel hook with a force transducer (AE 801,
Microelectronics, Horton, Norway) as previously described [43].
Fibers were immersed in 2.5 ml chambers placed into a
temperature-controlled bath at 22uC. Briefly, SR calcium loading
was initiated at pCa 6.5 in the presence of exogenous ATP, with or
without endogenous mitochondrial ATP production and/or
creatine kinase system activation. Azide (2 mM) was used to block
mitochondrial ATP production, and solutions lacking phospho-
creatine (PCr used at 12 mM) were used to block creatine kinase
activity. SR calcium release was elicited with 5 mM caffeine, and
was detected by measuring the resulting contractile force transient.
Figure 7. Summary of possible modes of action of resveratrol.
doi:10.1371/journal.pone.0026391.g007
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assessed by stepwise increasing the calcium concentration in the
presence of caffeine and was used as an endogenous calibration of
calcium concentration around the fibers. [Calcium]-time integral
was calculated to estimate calcium uptake occurring before
caffeine challenge. Results are expressed as absolute value for
MITO+PCr or relative to the load with ATP alone. pCa-tension
relationship allowed to calculate resting and maximal developed
force. Force was normalized to cross sectional fiber area and
expressed as mN.mm
22. Data were analyzed using a linearization
of the Hill equation F (relative force)=[Ca
nH/(K+[Ca]). The Hill
coefficient (nH) and the pCa for half maximal activation
pCa50=(2log10 K)/
nH were computed.
Real-time quantitative PCR analysis
Real-time PCR was performed using TaqMan Low Density
Array (TLDA) technology. TLDA were designed to amplify 48
cDNA for each sample as follows: 43 target genes involved in
energy metabolism and mitochondrial function and 5 housekeep-
ing genes (Table S5). For more details see Methods S1 available in
the online supporting information.
Immunoblotting
SERCA2, calsequestrin and eNOS expression, and AMPK
phosphorylation were assessed on proteins extracts from hearts or
aorta and/or resveratrol-treated adult rat ventricular myocytes by
immunobloting as detailed in Methods S1.
Biochemical studies
Frozen tissue samples were weighed, homogenized (Bertin
Precellys 24) in ice-cold buffer (50 mg/ml) containing (mM) 5
HEPES (pH 8.7), 1 EGTA, 1 DTT and 0.1% Triton X-100.
Citrate synthase (CS), cytochrome oxidase (COX) and total
creatine kinase (CK) as well as CK isoforms activities were
determined in homogenized ventricles as previously described
[37].
SIRT1 activity was assessed in ventricles using a SIRT1
fluorimetric assay kit (BIOMOL, EnzoLifeSciences) following an
adapted procedure. Briefly, 25 mg of total protein were incubated
with 15 ml of Fluor de Lys-Sirt1 substrate (100 mM) and NAD
+
(100 mM) at 37uC for 30 min. The reaction was stopped by the
addition of 50 ml of developer reagent containing nicotinamide
(2 mM) and the fluorescence was subsequently monitored for
45 min at 360 nm (excitation) and 460 nm (emission). The change
in fluorescence (arbitrary fluorescence units, AFU) per minute was
normalized to the amount of total protein in the sample.
Statistical analysis
Data are expressed as mean6SEM. The survival of the animals
was analyzed by the Kaplan-Meier method with a log-rank test.
Other data were analyzed by ANOVA followed by Student–
Newman–Keuls post hoc test. For aortic relaxation, curves have
been analyzed using repeated measure ANOVA followed by
Tukey’s multiple comparison test. Statistical significance between
groups was defined as p,0.05.
Supporting Information
Figure S1 mRNA expression of mitochondrial and
energy metabolism selected proteins. This figure includes
total results of TLDA experiments. *P,0.05 vs LS;
$P,0.05 vs
HS-NT.
(TIF)
Table S1 Lipid and glucose profile in blood samples.
Total cholesterol, HDL and LDL were significantly increased in
HS-NT compared to LS animals and tended to decrease with
RSV treatment. No significant change in blood triglycerides and
glucose was observed whatever the groups.
(DOC)
Table S2 Echocardiography and blood pressure mea-
surements. Table shows all echocardiographic analysis and
blood pressure data performed at 3 weeks and 11 weeks. As HS-
NT and HS-RSV groups showed no difference at 3 weeks, data
were pooled (HS group). At 11 weeks, systolic and diastolic
dysfunction was evident in HS-NT animals and could be largely
prevented by resveratrol treatment. Resting, maximal and mean
blood pressures were increased in HS-NT animals but were not
improved by resveratrol treatment.
(DOC)
Table S3 Mechanical parameters and calcium homeo-
stasis. No major change in force and calcium sensitivity was
observed in HS-NT rats except a decrease in the Hill coefficient
that was not prevented by resveratrol. The tendency to decrease of
the maximal SR calcium content (with optimal substrate
ATP+MITO+PCr) and of SERCA2 protein content in HS-NT
rats was prevented by resveratrol but these results did not reach
significance.
(DOC)
Table S4 Composition of the diet.
(DOC)
Table S5 Design of TaqMan Low Density Arrays.
(DOC)
Methods S1 Supplementary Methods and Results.
(DOC)
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